drugset / Trial / NCT01366092
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Phase 2
Active not recruiting
35 enrolled
Dana-Farber Cancer Institute
National Cancer Institute (NCI) · collabPrometheus Laboratories · collab
NaSingle-groupOpen-labelTreatment
Summary
Chronic GVHD is a medical condition that may occur after a bone marrow, stem cell or cord blood transplant. The donor's immune system may recognize the your body (the host) as foreign and attempt to 'reject' it. This process is known as graft-versus-host-disease. It is thought that IL-2 may help control chronic GVHD by stopping the donor's immune system from 'rejecting' your body. In this research study, we are looking to see how IL-2 can be used in combination with steroids to treat cGVHD.
Timeline
- Start
- 2011-07
- Primary completion
- 2014-10
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 1e+06 iu | Subcutaneous |